Comparative Pharmacology
Head-to-head clinical analysis: TRI SPRINTEC versus TRIPHASIL 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI SPRINTEC versus TRIPHASIL 21.
TRI-SPRINTEC vs TRIPHASIL-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus to impair sperm penetration and endometrial receptivity.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
One tablet orally daily for 21 days, followed by 7 drug-free days. Each tablet contains levonorgestrel 0.05 mg and ethinyl estradiol 0.03 mg (days 1-6), levonorgestrel 0.075 mg and ethinyl estradiol 0.04 mg (days 7-11), and levonorgestrel 0.125 mg and ethinyl estradiol 0.03 mg (days 12-21).
None Documented
None Documented
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Levonorgestrel: 10-45 hours (terminal, biphasic); ethinyl estradiol: 10-27 hours (terminal, triphasic). Clinical context: Steady state reached after 7-14 days with daily dosing.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Renal: 30-50% (ethinyl estradiol and levonorgestrel metabolites as glucuronide and sulfate conjugates). Fecal: 30-50% (biliary excretion of unconjugated metabolites). Unchanged drug: negligible.
Category C
Category C
Oral Contraceptive
Oral Contraceptive